Importantly, whereas “acquired resistance” is predominantly the consequence of estrogen-independent activation of ERα in cancer cells still harboring an intact ERα signaling axis, “intrinsic resistance” is mostly likely due to down-regulation/loss of ERα expression leading to endocrine panresistance and tumor progression and represents a serious challenge for the treatment of ERα+ breast cancer patients [3]. This evidence concerns the gene ESR1 and cancer.